23 February 2004
Futura Medical plc announces early progress in proof of concept study
Futura Medical plc ("Futura"), the AIM-quoted pharmaceutical and medical device group that develops innovative products for the sexual healthcare market, announces that an effective, simple technique for instilling measured doses of gel containing a vasodilator during continuous vaginal photoplethysmography has been developed by the clinical team who are conducting a proof of concept study at the Porterbrook Clinic in Sheffield .
The technique has allowed the measurement of a difference in vaginal blood circulation (a surrogate marker for lubrication) between the application of an active gel and a placebo gel.
This information will be published in the form of a poster at the upcoming conferences:
- 7th Congress of the European Federation of Sexology in Brighton , 1216 May 2004
- International Academy Sex Research (IASR) meeting In Helsinki , 16-20 June 2004
- International Society for the Study of Women’s Sexual Health (ISWSSH), summer 2004
James Barder , Chief Executive of Futura Medical plc, said: ”Whilst we are pleased with the initial progress of the female proof of concept study, this needs to be completed before any conclusions can be drawn. The purpose of the announcement is to enable the Porterbrook Clinic openly to discuss its clinical study methodology at these forthcoming important sexual health conferences as agreed under the terms of the study contract.”